Tue, May 20, 8:01 PM (33 days ago)
**Mosaic ImmunoEngineering, Inc. (MOSC) Q1 2025 Financial Summary** **Financial Health and Performance:** Mosaic ImmunoEngineering, Inc. (MOSC) reported a net loss of $181,320,000 for Q1 2025, a decrease from the $288,492,000 loss in Q1 2024. The company's cash and cash equivalents decreased to $85,930,000 from $115,019,000 in the previous quarter. Total current liabilities increased to $5,656,681,000, up from $5,537,270,000. The company's stockholders' deficit widened to $6,969,494,000 from $6,788,174,000. **Revenue and Profit Margins:** MOSC reported no revenue for Q1 2025, consistent with the previous quarter. Operating expenses decreased to $174,774,000 from $268,766,000 in Q1 2024, primarily due to reduced research and development and general and administrative expenses. The company's loss from operations was $174,774,000, an improvement from the $268,766,000 loss in the prior year period. **Cash Flow:** Net cash used in operating activities was $29,089,000 for Q1 2025, an improvement from the $91,139,000 used in Q1 2024. The change in cash and cash equivalents was a decrease of $29,089,000, compared to a decrease of $91,139,000 in the previous year period. **Earnings Changes:** The company's basic and diluted loss per common share was $0.03 for Q1 2025, an improvement from the $0.04 loss in Q1 2024. The weighted average number of common shares outstanding remained consistent at 7,236,447. **Quarterly Performance Discussion:** MOSC's financial performance for Q1 2025 reflects continued operational challenges, with significant losses and a widening stockholders' deficit. The company's ability to continue operations is highly dependent on its ability to raise additional capital. Management has expressed substantial doubt regarding the company's ability to continue as a going concern. **Trends and Uncertainties:** MOSC faces several uncertainties, including the ability to raise additional capital, the impact of economic conditions on investor decisions, and the potential for substantial dilution of existing stockholders. The company is pursuing a potential transaction with Oncotelic Therapeutics, Inc., which could provide new technologies and funding but also presents risks and uncertainties. **Future Operations Impact:** MOSC's future operations will depend on its ability to secure additional financing, advance its product candidates, and manage its financial obligations. The company's strategic initiatives, including the potential transaction with Oncotelic, will be critical in determining its future trajectory. However, the company's financial situation and market conditions present significant challenges and risks.